Immunic, Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, July 14, 2021 /PRNewswire/ — Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases,…
